Advertisement

Infarct Size Limitation: Principles and Problems

  • D. J. Hearse
  • D. M. Yellon
Conference paper
  • 59 Downloads
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 1)

Abstract

During the last 15 years the concept of therapeutic infarct size limitation has become well established, with many experimental and clinical studies producing encouraging results [18–20, 26]. However, during the last two to three years there have been an increasing number of experimental reports [4, 12, 14, 21, 27] have begun questioning whether traditional “anti-infarct” agents such as beta blockers [24, 25] are really able to limit myocardial infarct size [10]. In a major review of the effects of drugs upon evolving myocardial infarction, Opie in 1980 [23] cautiously concluded that the “time has not yet come so introduce anti-infarct agents into general cardiological practice”.

Keywords

Infarct Size Coronary Occlusion Border Zone Infarct Size Reduction Myocardial Infarct Size 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ahumada G, Roberts R, Sobel BE (1976) Evaluation of myocardial infarction with enzymatic indices. Prog Cardiovasc Dis 18: 405–420PubMedCrossRefGoogle Scholar
  2. 2.
    Baker JE, Hearse DJ (1983) Slow channel blockers and the calcium paradox: comparative studies in the rat with seven drugs. J Mol Cell Cardiol 15: 475–485PubMedCrossRefGoogle Scholar
  3. 3.
    Chagrasulis RW, Downey JM (1977) Selective coronary embolization in closed chest dogs. Am J Physiol 233: 335–337Google Scholar
  4. 4.
    Chambers DE, Yellon DM, Hearse Dj, Downey JM (1983) Effects of flurbiprofen in altering the size of myocardial infarcts in dogs: reduction or delay. Am J Cardiol 51: 884–890PubMedCrossRefGoogle Scholar
  5. 5.
    Darsee JR, Kloner RA, Braunwald E (1981) Demonstration of lateral and epicardial border zone salvage by flurbiprofen an in vivo method for assessing myocardium at risk. Circulation 63: 29–35 (retracted)Google Scholar
  6. 6.
    Factor, SM, Sonneblick EH, Kirk E (1978) The histological border zone of acute myocardial infarction - islands or peninsulas. Am J Path 92: 111–120PubMedGoogle Scholar
  7. 7.
    Factor SM, Cho S, Kirk E (1982) Non-specificity of triphenyl tetrazolium chloride (TC) for the gross diagnosis of acute myocardial infarction. Circulation 66, Suppl 11, 84Google Scholar
  8. 8.
    Harken AH, Barlow CH, Harden WR, Chance B (1981) Two and three dimensional display of myocardial ischemic “border zone” in dogs. Am J Cardiol 42: 1321–1334Google Scholar
  9. 9.
    Hearse DJ, Humphrey SM (1975) Enzyme release during myocardial anoxia: a study of metabolic protection. J Mol Cell Cardiol 7:463–-482Google Scholar
  10. 10.
    Hearse DJ, Yellon DM (1984) Therapeutic Approaches to Myocardial Infarct Size Limitation. Raven, New YorkGoogle Scholar
  11. 11.
    Hearse DJ, Yellon DM (1981) The border zone in evolving myocardial infarction: controversy or confusion? Am J Cardiol 47: 1321–1334PubMedCrossRefGoogle Scholar
  12. 12.
    Hearse DJ, Crome R, Yellon DM, Wyse R (1983) Metabolic and flow correlates of myocardial ischemia. Cardiovasc Res 17: 452–458PubMedCrossRefGoogle Scholar
  13. 13.
    Hearse DJ (1984) Critical distinctions in the modification of myocardial cell injury. In: Opie LH eds. Calcium antagonists and cardiovascular disease. Raven, New York 129–145Google Scholar
  14. 14.
    Heng MK, Norris RM, Peter T, Nisbet HD, Sing BN (1978) The effects of glucose-insulinpotassium on experimental infarction in the dog. Cardiovasc Res 12: 429–435PubMedCrossRefGoogle Scholar
  15. 15.
    Jugdutt BI, Hutchins GM, Bulkley BH, Becker LC (1981) Dissimilar effects of prostacylin, prostaglandin E1 and prostaglandin E2 on myocardial infarct size after coronary occlusion in conscious dogs. Circ Res 49: 685–700PubMedCrossRefGoogle Scholar
  16. 16.
    Kirlin PG, Romson JL, Pitt B, Abrams GD, Schork MA, Lucchesi BR (1980) Ibuprofen mediated infarct size reduction: effects of regional myocardial function in canine myocardial infarction. Am J Cardiol 50: 849–856CrossRefGoogle Scholar
  17. 17.
    Klein HH, Puschmann P, Schaper J, Schaper W (1981) The mechanism of the tetrazolium reaction in identifying experimental myocardial infarction. Virch Archiv 393: 287–297Google Scholar
  18. 18.
    Kloner RA, Braunwald E (1980) Observation in experimental myocardial ischemia. Cardiovasc Res 14: 371–395PubMedCrossRefGoogle Scholar
  19. 19.
    Maroko PR, Kjekshus JK, Sobel BE, Covell JW, Braunwald E (1971) Factors influencing infarct size following experimental coronary occlusion. Circulation 43: 67–82PubMedCrossRefGoogle Scholar
  20. 20.
    Maroko PR, Braunwald E (1983) Modification of myocardial infarct size after coronary occlusion. Ann Intern Med 97: 720–733Google Scholar
  21. 21.
    Most AS, Capone RJ, Mastrofrancesco PA (1976) Failure of hyaluronidase to alter the early course of acute myocardial infarction in pigs. Am J Cardiol 38: 28–33PubMedCrossRefGoogle Scholar
  22. 22.
    Newman PE (1981) The coronary collateral circulation: determinants and functional significance on ischemic heart disease. Am Heart J 102: 431–445PubMedCrossRefGoogle Scholar
  23. 23.
    Opie LH (1980) Myocardial infarct size Part II. Comparison of anti-infarct effects of beta blockade, glucose-insulin-potassium, nitrates and hyaluronidase. Am Heart J 100: 531–552PubMedCrossRefGoogle Scholar
  24. 24.
    Peter T, Heng MK, Singh BN, Ambler P, Nisbet IT, Elliot R, Norris R (1978) Failure of high doses of propranolol to reduce experimental myocardial ischemic damage. Circulation 57: 534–540PubMedCrossRefGoogle Scholar
  25. 25.
    Reimer KA, Jennings RB (1982) Decreasing myocardial energy utilization. In: Wagner GS ed Myocardial Infarct: measurement and intervention Martinus London 397–414Google Scholar
  26. 26.
    Rude RE, Muller JE Braunwald E (1981) Efforts to limit the size of myocardial infarcts. Ann Intern Med 95: 736–761PubMedGoogle Scholar
  27. 27.
    Vogel VM, Yannoni VG, Abrams GD, Lucchesi BR (1977) Inability of methylprednisolone sodium succinate to decrease infarct size or preserve enzyme activity measured 24 hours after coronary occlusion in the dog. Circulation 55: 588–595PubMedCrossRefGoogle Scholar
  28. 28.
    Yellon DM, Hearse DJ, Crome R, Grannell J, Wyse RKH (1981) Characterization of the lateral interface between normal and ischemic tissue in the canine heart evolving myocardial infarction. Am J Cardiol 47: 1233–1239PubMedCrossRefGoogle Scholar
  29. 29.
    Yellon DM, Hearse DJ, Crome R, Wyse RKH (1983) Temporal and spatial characteristics of evolving cell injury during regional myocardial ischaemia in the dog. The “border zone” controversy. J Am Coll Cardiol 2: 661–671Google Scholar
  30. 30.
    Yellon DM, Maxwell MP, Hearse DJ, Yoshida S, Eddy L, Downey JM (1985). Infarct size limitation: real or artefactual. Studies with flurbiprofen using a reperfusion model In: Dhallas NS, Hearse DJ (eds) Advances in Myocardiology, Vol 6, Plenum Press 619–628Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • D. J. Hearse
  • D. M. Yellon

There are no affiliations available

Personalised recommendations